Market Closed -
Hong Kong S.E.
04:08:20 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
1.03
HKD
|
+5.10%
|
|
+11.96%
|
-36.42%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
7,579
|
5,554
|
2,300
|
2,300
|
-
|
Enterprise Value (EV)
1 |
5,493
|
3,783
|
3,552
|
2,300
|
2,300
|
P/E ratio
|
-39.4
x
|
-12.1
x
|
-7.36
x
|
-13.4
x
|
-204
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
37.7
x
|
22.1
x
|
10.6
x
|
5.13
x
|
3.84
x
|
EV / Revenue
|
37.7
x
|
22.1
x
|
10.6
x
|
5.13
x
|
3.84
x
|
EV / EBITDA
|
-66
x
|
-38.5
x
|
-12.8
x
|
-12.1
x
|
-53.5
x
|
EV / FCF
|
-28.1
x
|
-24.3
x
|
-7.73
x
|
-10.7
x
|
-35.9
x
|
FCF Yield
|
-3.56%
|
-4.11%
|
-12.9%
|
-9.35%
|
-2.78%
|
Price to Book
|
2.37
x
|
2.02
x
|
0.95
x
|
1.06
x
|
1.06
x
|
Nbr of stocks (in thousands)
|
2,403,564
|
2,409,385
|
2,412,593
|
2,412,593
|
-
|
Reference price
2 |
3.153
|
2.305
|
0.9534
|
0.9534
|
0.9534
|
Announcement Date
|
3/29/22
|
3/29/23
|
3/27/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
21.5
|
103.9
|
200.8
|
251
|
336.2
|
448.5
|
599.3
|
EBITDA
1 |
-
|
-228
|
-114.8
|
-144.4
|
-277.2
|
-190
|
-43
|
EBIT
1 |
-
|
-252.5
|
-159.2
|
-222.6
|
-313.7
|
-204.8
|
-29.07
|
Operating Margin
|
-
|
-242.94%
|
-79.3%
|
-88.67%
|
-93.29%
|
-45.67%
|
-4.85%
|
Earnings before Tax (EBT)
1 |
-
|
-398.1
|
-182.7
|
-451.3
|
-463.6
|
-169.4
|
-8.455
|
Net income
1 |
-144.5
|
-398.1
|
-183.3
|
-454.4
|
-471.5
|
-169.4
|
-8.788
|
Net margin
|
-672.13%
|
-383.02%
|
-91.26%
|
-181.02%
|
-140.25%
|
-37.77%
|
-1.47%
|
EPS
2 |
-
|
-0.2300
|
-0.0800
|
-0.1900
|
-0.2000
|
-0.0712
|
-0.004670
|
Free Cash Flow
1 |
-
|
-141.4
|
-269.9
|
-228.5
|
-297.7
|
-215
|
-64
|
FCF margin
|
-
|
-136.01%
|
-134.43%
|
-91.02%
|
-83.53%
|
-47.93%
|
-10.68%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
1/25/21
|
3/30/21
|
3/29/22
|
3/29/23
|
3/27/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
597
|
2,086
|
1,771
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-141
|
-270
|
-228
|
-298
|
-215
|
-64
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-13.3%
|
-15.5%
|
-12.6%
|
-7.25%
|
-0%
|
ROA (Net income/ Total Assets)
|
-
|
-48%
|
-8.19%
|
-14.3%
|
-11.6%
|
-7%
|
-
|
Assets
1 |
-
|
829
|
2,237
|
3,182
|
2,898
|
2,420
|
-
|
Book Value Per Share
2 |
-
|
-5.700
|
1.330
|
1.140
|
1.000
|
0.9000
|
0.9000
|
Cash Flow per Share
2 |
-
|
-0.0600
|
-0.0700
|
-0.0800
|
-0.0900
|
-
|
-
|
Capex
1 |
-
|
62.6
|
108
|
45.9
|
90
|
65
|
50.5
|
Capex / Sales
|
-
|
60.23%
|
54%
|
18.3%
|
25.25%
|
14.49%
|
8.43%
|
Announcement Date
|
1/25/21
|
3/30/21
|
3/29/22
|
3/29/23
|
3/27/24
|
-
|
-
|
Last Close Price
0.9534
CNY Average target price
2.412
CNY Spread / Average Target +153.01% Consensus |
1st Jan change
|
Capi.
|
---|
| -36.42% | 317M | | +12.07% | 128B | | -9.04% | 10.65B | | +0.91% | 8.82B | | +16.72% | 7.19B | | +25.15% | 4.99B | | +7.17% | 3.4B | | -1.36% | 3.03B | | -8.73% | 2.14B | | -10.15% | 2B |
Medical Devices & Implants
|